Purple Biotech Announces Initiation of Phase 1b/2 Clinical Trial of CM24 for Treatment of Multiple Advanced Cancers
19 mars 2021 08h00 HE
|
Purple Biotech Ltd.
Study Being Conducted in Clinical Collaboration with Bristol Myers Squibb Preliminary Data from First Part of Study Expected to be Available in Second Half of 2021 REHOVOT, Israel, March 19,...
Purple Biotech to Present Additional Mechanism of Action Data for NT219 at American Association of Cancer Research 2021 Annual Meeting
11 mars 2021 08h02 HE
|
Purple Biotech Ltd.
TEL AVIV, Israel, March 11, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” ”, or the “Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and...
Purple Biotech Appoints Biopharmaceutical Industry Veteran Robert Gagnon to Board of Directors
03 mars 2021 07h00 HE
|
Purple Biotech Ltd.
Rehovot, Israel, March 03, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective, and durable therapies...
Purple Biotech Provides Corporate Update and Reports Second Half and Full Year 2020 Financial Results
02 mars 2021 07h00 HE
|
Purple Biotech Ltd.
Rehovot, Israel, March 02, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective, and durable therapies...
Purple Biotech to Present at the B. Riley Oncology Investor Conference
18 janv. 2021 07h41 HE
|
Kitov Pharma Ltd.
REHOVOT, Israel, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class therapies to overcome tumor immune...
Purple Biotech to Ring the Nasdaq Stock Market Opening Bell
04 janv. 2021 09h40 HE
|
Kitov Pharma Ltd.
Virtual Bell-Ringing Ceremony in Celebration of Company’s Recent Name Change to Purple Biotech REHOVOT, Israel, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (the “Company”)...
Kitov Announces Name Change to Purple Biotech Ltd.
10 déc. 2020 08h18 HE
|
Kitov Pharma Ltd.
New Name Reflects Company’s Evolution to Advancing First-in-Class Oncology Therapies TEL AVIV, Israel, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (the “Company”) (NASDAQ/TASE: KTOV),...
Kitov Pharma to Participate in November Investor Conferences
11 nov. 2020 07h25 HE
|
Kitov Pharma Ltd.
TEL AVIV, Israel, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov Expands Planned Phase 1/2 Clinical Trial of CM24 in Non-Small Cell Lung Cancer with New Cohort to Evaluate CM24 in Patients with Pancreatic Cancer Conducted with Bristol Myers Squibb
09 nov. 2020 07h30 HE
|
Kitov Pharma Ltd.
TEL AVIV, Israel, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and...
Kitov Pharma Receives Notice of Allowance for a U.S. Patent Covering its Anti-Cancer Drug Candidate, NT219
27 oct. 2020 08h03 HE
|
Kitov Pharma Ltd.
Patent covers NT219’s combinations with multiple 2nd and 3rd generation EGFR inhibitors, including osimertinib (TAGRISSO®) TEL AVIV, Israel, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma...